| San Diego Business Journal

Medical Tourism Still Needs A Shot in the Arm

A medical tourism campaign touting San Diego’s hospitals, genomics companies and sunny weather is trying to find its groove.

Epipen Alternative to Bring Good News to Price Sensitive Users

Adamis Pharmaceuticals’ epipen alternative will launch nationally in the first quarter of next year, the company said in a recent update.

Life Science Funding Shows Increase in Most Rounds

Financing rounds since 2013 have grown larger in San Diego life sciences. A look at annual median deal size shows an increase, from early-stage seed financing to Series A, C and D rounds. Only Series B rounds have remained flat in recent years.

Neurocrine’s Tourette Syndrome Drug Misses Primary Goal

San Diego-based Neurocrine’s drug for Tourette syndrome failed to meet its primary goal in a mid-stage clinical trial, the company reported Dec. 12.

Following the Local Biotech VC Funding Trail

The San Diego Business Journal frequently chronicles local funding rounds and the big dreams that accompany them. But what about the largest venture capital sources locally?

House Bill Would Further Delay Medical Device Tax

Recently proposed legislation would further push back a 2.3 percent excise tax on medical device makers, San Diego’s ResMed, NuVasive and Ra Medical Systems among them.

Healthcare District Dumps At-Large Elections

HEALTH: Grossmont Makes Move; Palomar Considers Election Change

Under the threat of a lawsuit from a Malibu attorney, one San Diego hospital district is moving to a new type of election system, while another will consider doing so.